早期宫颈癌术后辅助治疗:序贯放化疗优于单纯放疗与同步放化疗的III期随机试验
STARS III期随机试验纳入1048例FIGO IB-IIA期宫颈癌根治术后伴不良病理因素患者,1:1:1随机接受单纯放疗、同步放化疗或序贯放化疗。序贯放化疗较单纯放疗显著提高3年无病生存率(90.0% vs 82.0%)并降低癌症死亡风险,且优于同步放化疗(3年DFS 90.0% vs 85.0%);同步放化疗与单纯放疗无显著差异。
要点
- 序贯放化疗较单纯放疗显著提高3年无病生存率(90.0% vs 82.0%,HR 0.52)。
- 序贯放化疗较同步放化疗提高3年无病生存率(90.0% vs 85.0%,HR 0.65)。
- 同步放化疗与单纯放疗在无病生存和癌症死亡风险上无显著差异。
核心结论
- 在早期宫颈癌术后辅助治疗中,序贯放化疗较单纯放疗提高无病生存率并降低癌症死亡风险,且优于同步放化疗;同步放化疗与单纯放疗无显著差异。
研究设计与样本
- 共1048例FIGO IB-IIA期宫颈癌伴不良病理因素患者纳入分析,按1:1:1随机接受单纯放疗(350例)、同步放化疗(345例)或序贯放化疗(353例)。
主要发现
- 序贯放化疗组3年无病生存率为90.0%,单纯放疗组为82.0%(HR 0.52,95%CI 0.35-0.76)。
- 序贯放化疗组3年无病生存率为90.0%,同步放化疗组为85.0%(HR 0.65,95%CI 0.44-0.96)。
- 校正淋巴结受累后,序贯放化疗组5年癌症死亡风险低于单纯放疗组(92.0% vs 88.0%,HR 0.58,95%CI 0.35-0.95)。
- 同步放化疗与单纯放疗在无病生存和癌症死亡风险上均无显著差异。
关键数值与推荐
- 单纯放疗总剂量45-50 Gy;同步放化疗为每周顺铂30-40 mg/m2;序贯放化疗为顺铂60-75 mg/m2联合紫杉醇135-175 mg/m2,21天为一周期,放疗前2周期、放疗后2周期。
- 主要终点为3年无病生存率。
临床怎么用
- 对于早期宫颈癌根治术后伴不良病理因素的患者,可考虑序贯放化疗作为辅助治疗以改善无病生存。
- 同步放化疗在该人群中未显示优于单纯放疗,选择辅助方案时应权衡获益与毒性。
局限性
- 单纯放疗组淋巴结受累率最低(18.3%),基线特征除淋巴结受累外均衡。
- 癌症死亡风险分析在校正淋巴结受累后进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There is no current consensus on the role of chemotherapy in addition to radiation for postoperative adjuvant treatment of patients with early-stage cervical cancer with adverse pathological factors. OBJECTIVE: To evaluate the clinical benefits of sequential chemoradiation (SCRT) and concurrent chemoradiation (CCRT) compared with radiation alone (RT) as a postoperative adjuvant treatment in early-stage cervical cancer. DESIGN, SETTING, AND PARTICIPANTS: After radical hysterectomy at 1 of 8 participating hospitals in China, patients with FIGO (International Federation of Gynecology and Obstetrics) stage IB to IIA cervical cancer with adverse pathological factors were randomized 1:1:1 to receive adjuvant RT, CCRT, or SCRT. Data were collected from February 2008 to December 2018. INTERVENTIONS: Patients received adjuvant RT (total dose, 45-50 Gy), CCRT (weekly cisplatin, 30-40 mg/m2), or SCRT (cisplatin, 60-75 mg/m2, plus paclitaxel, 135-175 mg/m2) in a 21-day cycle, given 2 cycles before and 2 cycles after radiotherapy, respectively. MAIN OUTCOMES AND MEASURES: The primary end point was the rate of disease-free survival (DFS) at 3 years. RESULTS: A total of 1048 women (median [range] age, 48 [23-65] years) were included in the analysis (350 in the RT group, 345 in the CCRT group, and 353 in the SCRT group). Baseline demographic and disease characteristics were balanced among the treatment groups except that the rate of lymph node involvement was lowest in the RT group (18.3%). In the intention-to-treat population, SCRT was associated with a higher rate of DFS than RT (3-year rate, 90.0% vs 82.0%; hazard ratio [HR], 0.52; 95% CI, 0.35-0.76) and CCRT (90.0% vs 85.0%; HR, 0.65; 95% CI, 0.44-0.96). Treatment with SCRT also decreased cancer death risk compared with RT (5-year rate, 92.0% vs 88.0%; HR, 0.58; 95% CI, 0.35-0.95) after adjustment for lymph node involvement. However, neither DFS nor cancer death risk was different among patients treated with CCRT or RT. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, conducted in a postoperative adjuvant treatment setting, SCRT, rather than CCRT, resulted in a higher DFS and lower risk of cancer death than RT among women with early-stage cervical cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00806117.
引用
- Huang H, Feng YL, Wan T, et al. Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 33443541. doi:10.1001/jamaoncol.2020.7168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。